Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

(American Joint Committee on Cancer) stage III or stage IV BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600 mutant melanoma who are documented with progression of disease following treatment with a

vemurafenib
malignant melanoma of skin
pembrolizumab
solid tumour
measurable disease
  • 5 views
  • 09 May, 2021
  • 1 location
Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

BRAF V600-mutant metastatic melanoma are commonly treated using a combination of anti-BRAF and anti-MEK tyrosine kinase inhibitors (TKIs). The OPTIMEL trial aims to study the interest of

melanoma skin
advanced melanoma
malignant melanoma of skin
trametinib
braf v600 mutation
  • 4 views
  • 19 Feb, 2021
  • 5 locations
Dabrafenib Trametinib and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib

  • 0 views
  • 17 Apr, 2021
  • 2 locations
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

This phase II trial studies how well binimetinib and nivolumab work in treating patients with BRAF V600 wildtype melanoma that has spread to nearby tissues or lymph nodes and cannot be removed

  • 0 views
  • 23 May, 2021
  • 2 locations
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

The aim of the study was to evaluate the effectiveness of combination therapy with dabrafenib and trametinib (anti-BRAF and anti-MEK inhibitors) in the neoadjuvant treatment of BRAF-positive

  • 0 views
  • 16 Feb, 2021
  • 1 location
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

. The investigators will study the effect of short term oral anti-cancer drug combination, called dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), in improving thyroid cancer RAI absorption

  • 0 views
  • 13 Mar, 2021
  • 1 location
A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF-mutated advanced or metastatic solid tumors.

braf inhibitor
BRAF
cancer
  • 0 views
  • 26 Aug, 2021
  • 3 locations
Pembrolizumab Dabrafenib and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a

  • 0 views
  • 19 Aug, 2021
  • 1 location
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib and trametinib in stage IV disease to subjects with BRAF V600E mutant advanced

chemoradiotherapy
BRAF
trametinib
neutrophil count
metastasis
  • 13 views
  • 22 Jan, 2021
  • 1 location
A Combination of Vemurafenib Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

. The most common mutation is the substitution of valine for glutamic acid in position 600 of BRAF gene. The influence of this mutation was confirmed by G.Badalyan-Very et al. in 2010. About 64% of all

  • 0 views
  • 24 Jan, 2021
  • 1 location